Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab

ObjectiveAntitumour necrosis factor (anti-TNF) drugs impair protective immunity following pneumococcal, influenza and viral hepatitis vaccination and increase the risk of serious respiratory infections. We sought to determine whether infliximab-treated patients with IBD have attenuated serological r...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Gut 2021-05, Vol.70 (5), p.865-875
Hauptverfasser:	Butterworth, Jeffrey, Cooney, Rachel, Lees, Charlie W, Sebastian, Shaji, Bokth, Farjhana, Khalid, Nosheen, Kingston, Ashley, Naik, Kinnari, Bokth, Farjana, Fraser, Wendy, Thomas, Rachel, Howman, Ruth, Jansen, Lauren, Raine, Tim, Kapizioni, Christina, Hannington, Hayley, Nundlall, Kribashnie, Avanzi, Laura, Carungcong, Jaime, Grounds, Jenny, Ben Warner, Carmel Stuart, Lacey, Louise, Baker, Pearl, Collum, Joe, Shenoy, Achuth, Girshab, Waffa, Fowler, Emily, Stanton, Anna, Tripoli, Sherill, Hayes, Melony, Talbot, Alison, Sherris, Leanne, Hicks, Lucy, Cabreros, Leilani, Hunter, Sophie, Choong, Lee Meng, Vadamalayan, Babu, Foley, Stephen, Heeley, Cheryl, King, Sarah, Akhand, Rima, John, Anu, John, Maya, MacFaul, George, Scaletta, Diane, King, Andrew, Mohammed, Samera, Coke, Louise, Kolokouri, Eirini, Lockett, Melanie, Moran, Gordon, Khan, Neelam, Tarr, Lauren, Goulden, Kay, Dash, Joanne, Des DeSilva, Ofori Boateng, Ingram, Sarah, Hammonds, Fiona, Marriott, Suzie, Windak, Halina, Murray, Charles, Diaba, Cynthia, Pothecary, Carla, Deering, Lisa, Zagalo, Silvia, Russell, Richard, Henderson, Paul, Wilson, Jill, Burton, Helen, Cambridge, Vanessa, Ekblad, Charlotte, Ogor, Jonathan, Anthony, Alpha, Russell, Kalisha, Phillips, Anne, Abdulla, Muaad, Butterworth, Jeff, Brinkworth, Elaine, Moss, Alison, Ramadas, Arvind, Tregonning, Julie, Kunhunny, Swapna, Seaward, Abigail, Onovira, Felicia, Marsh, Liane, Habibi, Ruth, McNeill, Charlotte, Jones, Amy, Hayhurst, Caroline, Hindle, Julia, Bell, James, Blad, William, Johnston, Emma, Derikx, Lauranne, Siakavellas, Sryros, Baxter, Helen, Johns, Kerrie, Howard, Linda, Muddu, Ajay
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Antibodies Antibodies, Monoclonal, Humanized - therapeutic use Antibodies, Viral - immunology Antibody Formation - immunology autoimmune disease clarity Coronaviruses COVID-19 COVID-19 - epidemiology Disease transmission Drugs Evolution Female Gastrointestinal Agents - therapeutic use Hepatitis Hospitals Humans Immunoassay Immunomodulation Infections Inflammatory Bowel Disease Inflammatory Bowel Diseases - drug therapy Inflammatory diseases Infliximab Infliximab - therapeutic use Influenza Laboratories Male Middle Aged Monoclonal antibodies Pandemics Patients Prospective Studies Public health SARS-CoV-2 - immunology Seroconversion Serologic Tests Serology Severe acute respiratory syndrome coronavirus 2 Social distancing TNF inhibitors Tumor necrosis factor-TNF Tumor necrosis factor-α United Kingdom - epidemiology Vaccination Vaccines vedoluzimab
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	ObjectiveAntitumour necrosis factor (anti-TNF) drugs impair protective immunity following pneumococcal, influenza and viral hepatitis vaccination and increase the risk of serious respiratory infections. We sought to determine whether infliximab-treated patients with IBD have attenuated serological responses to SARS-CoV-2 infections.DesignAntibody responses in participants treated with infliximab were compared with a reference cohort treated with vedolizumab, a gut-selective anti-integrin α4β7 monoclonal antibody that is not associated with impaired vaccine responses or increased susceptibility to systemic infections. 6935 patients were recruited from 92 UK hospitals between 22 September and 23 December 2020.ResultsRates of symptomatic and proven SARS-CoV-2 infection were similar between groups. Seroprevalence was lower in infliximab-treated than vedolizumab-treated patients (3.4% (161/4685) vs 6.0% (134/2250), p
ISSN:	0017-5749 1468-3288
DOI:	10.1136/gutjnl-2021-324388